Bodhi Tree Biotechnology Inc (BDTB) EBIT (2024 - 2026)

Bodhi Tree Biotechnology (BDTB) has reported EBIT for 3 consecutive years, with -$23195.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT fell 16.12% year-over-year to -$23195.0 in Q2 2026; TTM through Jun 2026 was -$106806.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$147618.0, down 138.27% from the prior year.
• EBIT was -$23195.0 for Q2 2026 at Bodhi Tree Biotechnology, up from -$52949.0 in the prior quarter.
• Over five years, EBIT peaked at -$10687.0 in Q3 2025 and troughed at -$64777.0 in Q4 2024.
• A 3-year average of -$37293.7 and a median of -$37687.0 in 2025 frame the typical range for EBIT.
• Across the five-year window, EBIT advanced 18.26% in 2025 and dropped 16.12% in 2026, its largest moves.
• Over 3 years, EBIT stood at -$64777.0 in 2024, then grew by 18.26% to -$52949.0 in 2025, then jumped by 56.19% to -$23195.0 in 2026.
• The last three EBIT figures came in at -$23195.0 (Q2 2026), -$52949.0 (Q4 2025), and -$10687.0 (Q3 2025), per Business Quant data.